TrialHaematologica2024

Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.

Zachary D Epstein-Peterson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.